AstraZeneca jumps 4% after COPD drug wins Phase 3 trials. Tozorakimab success seen as rare win in tough COPD drug race.

AstraZeneca shares jump sharply amid strong premarket trading; Institutional activity reflects growing interest across healthcare sector; Biopharma pipeline continues ...

AstraZeneca — The pharma giant rose 3% after its experimental drug, tozorakimab, was found to meaningfully reduce flare-ups ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its business update and ...

The company is establishing commercial production capabilities to fuel plans to launch autologous CAR T cell therapies in ...

London’s FTSE 100 was flat at 9,976.77 in afternoon trade on Friday. AstraZeneca shot to the top of the index saying its ...

AstraZeneca PLC (LSE:AZN, STO:AZN, NYSE:AZN) disclosed on Friday that its Chief Executive Officer, Pascal Soriot, and Chief Financial Officer, Aradhana Sarin, were granted awards of ordinary shares ...

AstraZeneca PLC (LSE:AZN, STO:AZN, NYSE:AZN) reported Friday that awards of ordinary shares vested to two senior executives under the company’s Deferred Bonus Plan. The information was disclosed in a ...

AstraZeneca ( (GB:AZN) ) just unveiled an announcement.

British pharma major AstraZeneca (LSE: AZN) is stepping up its China strategy with plans to build a commercial cell therapy ...